This article is more than 5 years old. Information may no longer be current.
Phakic IOL achieves positive long-term results for moderate to high myopia in European trial
Click Here to Manage Email Alerts
BARCELONA — At 4 years of follow-up, the Alcon AcrySof Cache phakic IOL has achieved good visual results, and there have been limited adverse events, according to a presenter here.
Michael C. Knorz, MD, reported results of a phase 3 European multicenter non-randomized trial of 48 patients at 4 years after implantation at the European Society of Cataract and Refractive Surgeons meeting.
"Fourth-year outcomes in this European study demonstrate excellent visual acuities, stable refraction over time, very high predictability of refraction, and it's especially important that endothelial cell density was well within the expected limits and there was no progressive endothelial cell loss over the 4-year period," Dr. Knorz said. There was also no chronic inflammation and no unexpected safety issues.
The AcrySof Cache phakic IOL is a foldable, single-piece IOL made of a soft acrylic material, delivered through a Monarch II injector system, he said. It features a 6-mm optic with an overall length of 12.5 mm to 13.5 mm, although a 14 mm size is in development. The lens is currently available in –6 D to –16.5 D power in 0.5 D increments.